Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Grebien Florian,

Beiträge für wissenschaftliche Veranstaltungen

Vortrag

Eder, T; Grebien F (2020): Benchmarking differential ChIP-seq tools 4th Symposium on Comparative Medicine; January 30-31, 2020; Vienna, Austria. 2020.

Grebien, F (2020): Identifying novel targets and vulnerabilities in NUP98-fusion driven leukemia. Identifying novel targets and vulnerabilities in NUP98-fusion driven leukemia.; FEB 12, 2020; Düsseldorf, Germany. 2020.

Grebien, F (2020): Functional Genomics and CRISPR. CRISPR/Cas-Workshop; FEB 18, 2020; Assiut, Egypt. 2020.

Park, JS; Tin, G; de Araujo, ED; Orlova, A; Sorger, H; Grebien, F; Heyes, E; Geletu, M; Villalonga, R; Sampedro, A; Sedighi, A; Herling, M; Mustjoki, S; Eram, MS; Ahmar, S [and 7 others] (2020): A potent and selective small molecule degrader of STAT5 for the treatment of hematological malignancies. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 LB-108.

Eder, T; Grebien, F (2019): Benchmarking differential ChIP-seq tools. Mathematical Models in Cancer workshop; AUG, 1, 2019; Vienna, Austria. 2019.

Grebien, F (2019): Mechanistic studies of Leukemia Oncoproteins to find novel ways to efficiently target cancer – How many ways exist to kill AML cells? 1st Meeting of the Platform for Comparative Pathology; SEP 16, 2019; Krems, Austria. 2019.

Grebien, F (2019): Dissection of Oncogenic Networks in Fusion Protein-Driven Leukemia. Dissection of Oncogenic Networks in Fusion Protein-Driven Leukemia; Finsen Laboratory - BRIC - University of Copenhagen; DEC 13, 2019; Copenhagen, Denmark. 2019.

Grebien, F (2019): Modelling and Manipulating Fusion Protein-Driven Leukemia. Modelling and Manipulating Fusion Protein-Driven Leukemia; OCT 11, 2019; Basel, Switzerland. 2019.

Grebien, F (2019): Dissection of New Molecular Targets in AML. Precision Medicine in Hematology Working Conference 2019; SEP 20, 2019; Vienna, Austria. 2019.

Heyes, E; Grebien, F (2019): Functional Cooperation of CEBPA and TET2 mutations in Acute Myeloid Leukemia. Annual Meeting of the European Hematology Association (EHA); JUN 12, 2019; Amsterdam, Netherlands. 2019.

Grebien, F (2018): Functional Systems-Level studies of Fusion Oncoproteins in Leukemia. LBI-CR Annual Meeting Seggau; MAY 08, 2018; Seggau, Austria. 2018.

Grebien, F (2018): Modelling and Manipulating Oncogenic Networks in Leukemia 6th Vienna Symposium on Next Generation Sequencing; NOV 15, 2018; Vienna, Austria. 2018.

Grebien, F (2018): Picturing and Perturbing Genomic and Proteomic Networks of Oncogenic Fusion Proteins in Leukemia 2018 NOMIS Distinguished Scientist and Scholar Award ceremony; OCT 5, 2018; Zürich, Switzerland. 2018.

Grebien, F (2018): Identification of Actionable Nodes in Cancer-Specific Protein Networks. Mathematical Models in Cancer Workshop; JUL 20, 2018; Vienna, Austria. 2018.

Grebien, F (2018): Scientific and Social Implications of the CRISPR Technology. Research Platform for Responsible Research and Innovation in Academic Practice; MAY 11, 2018; Vienna, Austria. 2018.

Grebien, F (2018): Identification of Actionable Oncogenic Mechanisms in CEBPA-mutant AML. Biocenter; JUN 5, 2018; Munich, Germany. 2018.

Heyes, E; Schmidt, L; Eder, T; Volpe, G; Chatziathanasiou, K; Schmidt, C; Frampton, J; Grebien, F (2018): Functional cooperation of CEBPA and TET2 mutations in Acute Myeloid Leukemia. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

Schmidt, L; Heyes, E; Scheiblecker, L; Eder, T; Volpe, G; Frampton, J; Nerlov, C; Valent, P; Grembecka, J; Grebien, F (2018): CEBPA-mutant acute myeloid leukemia is sensitive to small-molecule-mediated inhibition of the Menin-MLL interaction. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 9-9.

Schmoellerl, J; Barbosa, I; Van der Veen, C; Eder, T; Schmidt, L; Brandstoetter, T; Maurer, B; Terlecki, S; Hormann, G; Valent, P; Jude, J; Sexl, V; Zuber, J; Grebien, F (2018): NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

Poster

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Valent, P; Zuber, J; Gray, N; Sexl, V (2019): CDK8 degradation – preparing the ground for mTOR inhibition in ALL. -AEK Congress 2019; Feb 27 - MAR 1, 2019; Heidelberg, Germany.

Ebner, J; Skucha, A; Grebien, F (2018): Functional Investigation of SETD2 in acute myeloid leukemia. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 79-80.

Grebien, F (2018): Science Cafe - Krebsforschungspavillon. Science Cafe - Krebsforschungspavillon; SEP 8, 2018; Vienna, Austria. 2018.

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Kubicek, S; Valent, P; Zuber, J; Gray, N; Sexl, V (2018): CDK8 degradation - Preparing the ground for mTOR inhibition in BCR/ABL+ ALL. -23rd Congress of the European Hematogloy Association; JUNI 14-17, 2018; Stockholm, Sweden. Open Access Logo

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit